AR059178A1 - Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. - Google Patents
Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.Info
- Publication number
- AR059178A1 AR059178A1 ARP070100305A ARP070100305A AR059178A1 AR 059178 A1 AR059178 A1 AR 059178A1 AR P070100305 A ARP070100305 A AR P070100305A AR P070100305 A ARP070100305 A AR P070100305A AR 059178 A1 AR059178 A1 AR 059178A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluororalkyl
- 3alkyl
- alkylene
- fluoralkyl
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 36
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- -1 C1-6 fluororalkoxy Chemical group 0.000 abstract 5
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 229910052740 iodine Chemical group 0.000 abstract 1
- 239000011630 iodine Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicacion 1: Un compuesto de acuerdo con la formula (1) donde, R1 se selecciona de hidrogeno, halo, alquilo C1-5, fluoralquilo C1-6, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3NH2, alquilen C1-3NH-alquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3-NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-6, fluoralcoxi C1-6, amino, NHalquilo C1-3, NHfluoralquil C1-3, N(alquil C1- 3)2, N(fluoralquil C1-3)2, N(alquil C1-3)-fluoralquilo C1-3, NH(CO)alquilo C1-3, NH(CO)fluoralquilo C1-3, NH(CO)alcoxi C1-3, NH(CO)fluoralcoxi C1-3, NHSO2alquilo C1-3, NHSO2fluoralquilo C1-3, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, COOH, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N (alquil C1-3)2-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6), ciano y SO2NH2, R2 se selecciona de hidrogeno, halo, alquilo C1-5, fluoralquilo C1-6, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3NH2, alquilen C1-3NH-alquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3-NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-6, fluoralcoxi C1-6, amino, NHalquilo C1-3, NHfluoralquil C1-3, N(alquil C1-3)2, N(fluoralquil C1-3)2, N(alquil C1-3)-fluoralquilo C1-3, NH(CO)alquilo C1-3, NH(CO)fluoralquilo C1-3, NH(CO)alcoxi C1-3, NH(CO)fluoralcoxi C1-3, NHSO2alquilo C1-3, NHSO2fluoralquilo C1-3, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, COOH, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N (alquil C1-3)2-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6) y ciano, o R1 y R2 juntos forman un anillo como se muestra en formula (2); R3 se selecciona de fluor, bromo, yodo, alquilo C1-4, fluoralquilo C1-4, trifluormetilo, alquilen C1-3-Oalquilo C1-3, alquilen C1-3-Ofluoralquilo C1-3, alquilen C1-3-NH2, alquilen C1-3-Nhalquilo C1-3, alquilen C1-3-N(alquilo C1-3)2, alquilen C1-3- NHfluoralquilo C1-3, alquilen C1-3-N(fluoralquilo C1-3)2, alquilen C1-3-N(alquil C1-3)-fluoralquilo C1-3, hidroxi, alcoxi C1-4, fluoralcoxi C1-4, amino, NHalquilo C1-3, NHfluoralquilo C1-3, N(alquilo C1-3)2, N(fluoralquilo C1-3)2, N(alquil C1-3)- fluoralquilo C1-3, NH(alquileno C0-3)G2, N(alquil C0-1 )N(alquilo C0-1)2, N(alquil C0-1)Oalquilo C0-1, NH(CO)alquiloC1-3, NH(CO)fluoralquilo C1-3, NH(CO)G2, (CO)alquilo C1-3, (CO)fluoralquilo C1-3, (CO)alcoxi C1-3, (CO)fluoralcoxi C1-3, (CO)NH2, (CO)NHalquilo C1-3, (CO)NHfluoralquilo C1-3, (CO)N(alquilo C1-3)2, (CO)N(fluoralquilo C1-3)2, (CO)N(alquil C1-3)-fluoralquilo C1-3, (CO)N(alquileno C4-6), (CO)N(fluoralquileno C4-6), (CO)NH2G2, SO2NH2, SO2NHalquilo C1-3, SO2NHfluoralquilo C1-3, SO2N(alquilo C1-3)2, SO2N(fluoralquilo C1-3)2, SO2N(alquil C1-3)-fluoralquilo C1-3, ciano, SO2alquilo C1-6, Salquilo C1-6, Sfluoralquilo C1-6, N(alquileno C4-6) y G1, donde G1 es como se muestra en formula (3); X5 se selecciona de O, NH, Nalquilo C1- 3, y Nfluoralquilo C1-3; G2 es fenilo o un heterociclo aromático de 5 o 6 miembros, sustituido en forma opcional con un sustituyente seleccionado de fluor, bromo, yodo, metilo y metoxi; Q es un heterociclo aromático de 6 miembros que contiene uno o dos átomos de N, donde X1, X2, X3 y X4 se seleccionan en forma independiente de N o C, y donde uno o dos de X1, X2, X3 y X4 es N y el restante es C, y si X4 es C, dicho C se sustituye en forma opcional con fluor o yodo; y uno o más de los átomos de formula (1) es opcionalmente un isotopo detectable; como base libre o una sal, solvato o solvato de una sal aceptable para uso farmacéutico del mismo, con la salvedad de que cuando R1 y R2 son H, R3 metilo, hidroxi, amino, aminofenilo, aminoacetilo o metoxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76265406P | 2006-01-27 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059178A1 true AR059178A1 (es) | 2008-03-12 |
Family
ID=38309497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100305A AR059178A1 (es) | 2006-01-27 | 2007-01-24 | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8163928B2 (es) |
| EP (1) | EP1981883A4 (es) |
| JP (1) | JP5289061B2 (es) |
| KR (1) | KR101406248B1 (es) |
| CN (1) | CN101410393B (es) |
| AR (1) | AR059178A1 (es) |
| AU (1) | AU2007207904C1 (es) |
| BR (1) | BRPI0707283A2 (es) |
| CA (1) | CA2640213A1 (es) |
| EC (1) | ECSP088645A (es) |
| IL (1) | IL192876A0 (es) |
| NO (1) | NO20083394L (es) |
| NZ (1) | NZ569667A (es) |
| RU (1) | RU2448106C2 (es) |
| SA (1) | SA07280009B1 (es) |
| TW (2) | TW201018678A (es) |
| UA (1) | UA95267C2 (es) |
| UY (1) | UY30112A1 (es) |
| WO (1) | WO2007086800A1 (es) |
| ZA (1) | ZA200806075B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201018678A (en) | 2006-01-27 | 2010-05-16 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| TW200901998A (en) | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
| US8557222B2 (en) | 2008-04-04 | 2013-10-15 | Avid Radiopharmaceuticals, Inc. | Radiopharmaceutical imaging of neurodegenerative diseases |
| ES2554772T3 (es) | 2008-05-30 | 2015-12-23 | Merck Sharp & Dohme Corp. | Azabenzoxazoles sustituidos novedosos |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| US20110212031A1 (en) * | 2008-10-31 | 2011-09-01 | Cyrille Sur | Novel substituted azabenzoxazoles |
| ES2620177T3 (es) * | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| EP2585455B1 (en) | 2010-06-24 | 2019-08-07 | The Regents of the University of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
| CN106729771A (zh) | 2011-04-21 | 2017-05-31 | 加利福尼亚大学董事会 | 官能化磁性纳米颗粒及在淀粉样沉积物和神经原纤维缠结成像中用途 |
| WO2013040183A1 (en) * | 2011-09-16 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof |
| CN102558091B (zh) * | 2011-12-22 | 2014-10-08 | 合肥工业大学 | 一种苯并噻唑类衍生物及其用途 |
| CN102659772B (zh) * | 2012-05-03 | 2015-02-11 | 北京师范大学 | 一种与Aβ斑块有亲和力的2-芳基苯并杂环化合物及其制备方法和应用 |
| CA2894994C (en) | 2012-12-21 | 2019-11-12 | National Institute Of Radiological Sciences | Compounds for imaging tau proteins that accumulate in brain |
| EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| WO2015051188A1 (en) * | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| US20170216252A1 (en) * | 2014-07-11 | 2017-08-03 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| JP6562361B2 (ja) * | 2014-07-16 | 2019-08-21 | 国立研究開発法人科学技術振興機構 | ベンゾチアゾール化合物及びこれを含有する医薬 |
| US10472346B2 (en) | 2014-10-31 | 2019-11-12 | The General Hospital Corporation | Potent gamma-secretase modulators |
| EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| BR112017011661A2 (pt) * | 2014-12-02 | 2018-03-06 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como agentes de controle de pragas. |
| KR102536024B1 (ko) * | 2015-03-12 | 2023-05-24 | 에프엠씨 코포레이션 | 헤테로환-치환 이환 아졸 살충제 |
| MX382156B (es) * | 2015-08-28 | 2025-03-13 | Chdi Foundation Inc | Sondas para formar imagenes de proteina de huntingtina. |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| CA3071525A1 (en) * | 2017-08-02 | 2019-02-07 | Spinogenix, Inc. | Benzothiazole and related compounds |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| US11844846B2 (en) | 2018-05-16 | 2023-12-19 | Emory University | Styrylbenzothiazole derivatives and uses in imaging methods |
| HRP20250780T1 (hr) * | 2019-01-31 | 2025-09-12 | Spinogenix, Inc. | Čvrsti oblici promotora spinogeneze |
| GB201914989D0 (en) * | 2019-10-16 | 2019-11-27 | Karin & Sten Mortstedt Cbd Solutions Ab | Selective ligands for TAU Aggregates |
| KR20220100921A (ko) | 2019-11-13 | 2022-07-18 | 아프리노이아 테라퓨틱스 리미티드 | 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도 |
| KR102682408B1 (ko) * | 2021-05-12 | 2024-07-05 | 에이치케이이노엔 주식회사 | 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도 |
| CN114380731B (zh) * | 2022-03-09 | 2024-07-02 | 台州学院 | 一种kcnq钾离子通道激动剂、药物组合物及其应用 |
| CN114478431B (zh) * | 2022-03-09 | 2024-07-02 | 台州学院 | 一种双取代苯并噻吩类钾离子通道激动剂的制备方法 |
| EP4612139A1 (en) | 2022-11-03 | 2025-09-10 | Sentonix, Inc. | Selective ligands for tau aggregates |
| WO2025202955A1 (en) | 2024-03-28 | 2025-10-02 | Pi Industries Ltd. | Fused bicyclic compounds and their use as pest control agents |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU523040B2 (en) * | 1978-05-15 | 1982-07-08 | Kanebo Limited | Calcium -antagonistic composition |
| GB8305245D0 (en) | 1983-02-25 | 1983-03-30 | Fujisawa Pharmaceutical Co | Imidazo-heterocyclic compounds |
| US4556411A (en) * | 1984-12-07 | 1985-12-03 | Fmc Corporation | Benzothiazole derivatives for plant growth and development modification |
| JPS6394248A (ja) | 1986-10-08 | 1988-04-25 | Canon Inc | 電子写真感光体 |
| CA2034309C (en) * | 1990-01-22 | 1997-04-01 | Takashi Iwaki | Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus |
| JPH09507071A (ja) | 1993-12-21 | 1997-07-15 | イーライ・リリー・アンド・カンパニー | アミロイド原性ペプチドに関連した状態を治療又は予防する方法 |
| US5518713A (en) * | 1995-02-13 | 1996-05-21 | 3V Inc. | Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them |
| JPH11116476A (ja) | 1997-10-16 | 1999-04-27 | Sankyo Co Ltd | 縮合複素環化合物 |
| HU230581B1 (hu) * | 2000-08-24 | 2017-01-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében |
| JP2004524289A (ja) * | 2000-12-22 | 2004-08-12 | アストラゼネカ・アクチエボラーグ | 治療化合物 |
| US6596731B2 (en) | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
| DE60217090T2 (de) | 2001-04-23 | 2007-07-12 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel |
| EP1460067A4 (en) * | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| GB0130305D0 (en) | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
| AU2003242233A1 (en) | 2002-06-12 | 2003-12-31 | Bf Research Institute, Inc. | Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation |
| TW200401194A (en) | 2002-07-11 | 2004-01-16 | Advanced Micro Devices Inc | Method and apparatus for determining a processor state without interrupting processor operation |
| EP1539151B1 (en) | 2002-08-02 | 2009-03-18 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| JP2004250411A (ja) | 2003-02-21 | 2004-09-09 | Bf Kenkyusho:Kk | アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物 |
| CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| CA2521056A1 (en) | 2003-03-31 | 2004-10-14 | Daiichi Pharmaceutical Co., Ltd. | Hydrazone derivative |
| US7329682B2 (en) * | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
| RU2340612C2 (ru) * | 2003-05-13 | 2008-12-10 | Ф.Хоффманн-Ля Рош Аг | 2-имидазобензотиазолы как лиганды аденозинового рецептора |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| CA2609980C (en) | 2005-05-27 | 2015-10-13 | Queen's University At Kingston | Treatment of protein folding disorders |
| US20080219922A1 (en) | 2005-09-12 | 2008-09-11 | Goodman Mark M | Alzheimer's Disease Imaging Agents |
| CN101355940B (zh) | 2005-09-16 | 2013-03-27 | 匹兹堡大学高等教育联邦体系 | 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法 |
| WO2007047204A1 (en) | 2005-10-11 | 2007-04-26 | University Of Pittsburgh | Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins |
| CA2627722A1 (en) * | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
| US8022075B2 (en) | 2005-11-30 | 2011-09-20 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| TW201018678A (en) | 2006-01-27 | 2010-05-16 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
| EP2023919A4 (en) * | 2006-05-08 | 2010-12-22 | Molecular Neuroimaging Llc | COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES |
| TW200813035A (en) * | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| EP2125800A1 (en) | 2007-01-22 | 2009-12-02 | AstraZeneca AB | Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives |
-
2007
- 2007-01-19 TW TW098145976A patent/TW201018678A/zh unknown
- 2007-01-19 TW TW096102118A patent/TW200736252A/zh unknown
- 2007-01-24 AR ARP070100305A patent/AR059178A1/es unknown
- 2007-01-24 SA SA7280009A patent/SA07280009B1/ar unknown
- 2007-01-25 NZ NZ569667A patent/NZ569667A/en not_active IP Right Cessation
- 2007-01-25 US US12/162,255 patent/US8163928B2/en not_active Expired - Fee Related
- 2007-01-25 RU RU2008130965/04A patent/RU2448106C2/ru not_active IP Right Cessation
- 2007-01-25 EP EP20070709290 patent/EP1981883A4/en not_active Withdrawn
- 2007-01-25 UA UAA200809015A patent/UA95267C2/ru unknown
- 2007-01-25 JP JP2008552268A patent/JP5289061B2/ja not_active Expired - Fee Related
- 2007-01-25 CA CA002640213A patent/CA2640213A1/en not_active Abandoned
- 2007-01-25 BR BRPI0707283-0A patent/BRPI0707283A2/pt not_active IP Right Cessation
- 2007-01-25 CN CN2007800112344A patent/CN101410393B/zh not_active Expired - Fee Related
- 2007-01-25 KR KR1020087020871A patent/KR101406248B1/ko not_active Expired - Fee Related
- 2007-01-25 WO PCT/SE2007/000068 patent/WO2007086800A1/en not_active Ceased
- 2007-01-25 AU AU2007207904A patent/AU2007207904C1/en not_active Ceased
- 2007-01-26 UY UY30112A patent/UY30112A1/es not_active Application Discontinuation
-
2008
- 2008-07-11 ZA ZA2008/06075A patent/ZA200806075B/en unknown
- 2008-07-17 IL IL192876A patent/IL192876A0/en unknown
- 2008-07-22 EC EC2008008645A patent/ECSP088645A/es unknown
- 2008-08-01 NO NO20083394A patent/NO20083394L/no not_active Application Discontinuation
-
2012
- 2012-04-23 US US13/453,579 patent/US8957215B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UY30112A1 (es) | 2007-08-31 |
| CN101410393B (zh) | 2012-01-25 |
| JP2009528271A (ja) | 2009-08-06 |
| TW201018678A (en) | 2010-05-16 |
| NO20083394L (no) | 2008-10-02 |
| CN101410393A (zh) | 2009-04-15 |
| US20090028787A1 (en) | 2009-01-29 |
| KR20080090542A (ko) | 2008-10-08 |
| ZA200806075B (en) | 2012-12-27 |
| WO2007086800A1 (en) | 2007-08-02 |
| EP1981883A1 (en) | 2008-10-22 |
| US8957215B2 (en) | 2015-02-17 |
| CA2640213A1 (en) | 2007-08-02 |
| AU2007207904C1 (en) | 2011-10-13 |
| UA95267C2 (en) | 2011-07-25 |
| IL192876A0 (en) | 2009-02-11 |
| US8163928B2 (en) | 2012-04-24 |
| AU2007207904A1 (en) | 2007-08-02 |
| BRPI0707283A2 (pt) | 2011-04-26 |
| ECSP088645A (es) | 2008-08-29 |
| SA07280009B1 (ar) | 2011-07-20 |
| KR101406248B1 (ko) | 2014-06-19 |
| AU2007207904B2 (en) | 2011-03-10 |
| TW200736252A (en) | 2007-10-01 |
| RU2448106C2 (ru) | 2012-04-20 |
| EP1981883A4 (en) | 2010-10-06 |
| JP5289061B2 (ja) | 2013-09-11 |
| US20120207679A1 (en) | 2012-08-16 |
| NZ569667A (en) | 2011-09-30 |
| RU2008130965A (ru) | 2010-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059178A1 (es) | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. | |
| ES2271615T3 (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos. | |
| AR061515A1 (es) | Benzoxazoles sustituidos con heteroarilo. composiciones farmaceuticas. | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| CO6270228A2 (es) | Derivados de quinazilinona 6-, 7-, u 8 -sustituidos y composiciones que los comprenden y metodos para usar los mismos | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| CR8859A (es) | Derivados de piridina | |
| UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
| ECSP045078A (es) | Tiofen- y tiazolsulfonamidas como agentes antineoplásicos | |
| AR062405A1 (es) | Derivados de isoindol | |
| AR063636A1 (es) | Derivados de indol y de benzofurano-2-carboxamida | |
| EA201070010A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| DOP2010000063A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| AR044453A1 (es) | Derivados de metoxi-pirazin-tienil sulfonamida | |
| AR054341A1 (es) | Combinaciones sinergicas de compuestos activos fungicidas | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| AR065903A1 (es) | Derivados nuevos de 2,3- benzodiazepina y su uso como agentes antipsicoticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |